| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1080/07357907.2016.1245317 |
| P698 | PubMed publication ID | 27824512 |
| P50 | author | Rezvan Najafi | Q56635642 |
| Saeid Afshar | Q56855046 | ||
| Hamed Manoochehri | Q90818950 | ||
| P2093 | author name string | Hamed Manoochehri Khoshinani | |
| Rezvan Najafi | |||
| Saeid Afshar | |||
| P2860 | cites work | Myeloid-derived suppressor cells: linking inflammation and cancer | Q24641811 |
| Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs | Q26774750 | ||
| Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radioresistance | Q26779535 | ||
| Progress toward overcoming hypoxia-induced resistance to solid tumor therapy | Q26796405 | ||
| Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response | Q27009437 | ||
| Targeting HIF-1 for cancer therapy | Q27860504 | ||
| Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis | Q28279053 | ||
| Targeting hypoxia in cancer therapy | Q29615491 | ||
| Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity | Q33186765 | ||
| PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation | Q33569771 | ||
| Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies | Q33877024 | ||
| Hypoxia, clonal selection, and the role of HIF-1 in tumor progression | Q33924693 | ||
| Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor Progression | Q34168497 | ||
| Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. | Q34238898 | ||
| Clostridia in cancer therapy | Q34307573 | ||
| Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response | Q34375447 | ||
| Role of oxygen radicals in DNA damage and cancer incidence. | Q34383781 | ||
| The role of hypoxia-activated prodrugs in cancer therapy | Q34571883 | ||
| Treatment resistance of solid tumors: role of hypoxia and anemia | Q34579410 | ||
| Targeting tumors with hypoxia-activated cytotoxins | Q34626133 | ||
| Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy | Q34775024 | ||
| Tumor hypoxia: a target for selective cancer therapy | Q35602696 | ||
| Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours | Q35685078 | ||
| Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. | Q35825254 | ||
| New anticancer strategies targeting HIF-1. | Q35864024 | ||
| Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis | Q43918986 | ||
| Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway | Q44019897 | ||
| 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. | Q44426540 | ||
| Development of a hypoxia-responsive vector for tumor-specific gene therapy | Q45866583 | ||
| Suppression of tumor growth through disruption of hypoxia-inducible transcription | Q45872806 | ||
| Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint | Q45878755 | ||
| A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. | Q50561584 | ||
| Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery. | Q50803523 | ||
| Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). | Q52594169 | ||
| AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial. | Q53245269 | ||
| Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels | Q35916654 | ||
| Tumor-activated prodrugs--a new approach to cancer therapy | Q35964429 | ||
| Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells | Q35994664 | ||
| Hypoxia and anemia: effects on tumor biology and treatment resistance | Q36090924 | ||
| Negative and positive regulation of HIF-1: a complex network | Q36182360 | ||
| Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer | Q36214623 | ||
| Clostridium spores as anti-tumour agents. | Q36405753 | ||
| HIF-1 and tumour radiosensitivity | Q36493239 | ||
| Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. | Q36751567 | ||
| Targeting hypoxia cell signaling for cancer therapy | Q36784388 | ||
| Hypoxia-driven selection of the metastatic phenotype | Q36801461 | ||
| Detection and characterization of tumor hypoxia using pO2 histography | Q36834948 | ||
| Tirapazamine: from bench to clinical trials. | Q37230218 | ||
| Hypoxia-specific gene expression for ischemic disease gene therapy | Q37460109 | ||
| Role of hypoxia in the hallmarks of human cancer | Q37500308 | ||
| Hypoxia-activated prodrugs in cancer therapy: progress to the clinic | Q37707385 | ||
| Bacteria in cancer therapy: a novel experimental strategy | Q37717794 | ||
| Hypoxia and hypoxia-inducible factors: master regulators of metastasis | Q37801762 | ||
| Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways | Q37861928 | ||
| Hypoxia-regulated microRNAs in human cancer | Q38078802 | ||
| Microenvironment and radiation therapy | Q38091084 | ||
| Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia | Q38120850 | ||
| Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling. | Q38177279 | ||
| Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment | Q38246724 | ||
| Prolyl hydroxylase inhibitors act as agents to enhance the efficiency of cell therapy | Q38577907 | ||
| Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. | Q39425368 | ||
| Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide | Q39456593 | ||
| Introduction of hypoxia-targeting p53 fusion protein for the selective therapy of non-small cell lung cancer | Q39605499 | ||
| Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells | Q39773550 | ||
| Significance of HIF-1-active cells in angiogenesis and radioresistance | Q40120839 | ||
| Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study | Q40123047 | ||
| Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. | Q40128344 | ||
| Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564. | Q40225838 | ||
| Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). | Q40848113 | ||
| Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting | Q40958050 | ||
| Targeting hypoxia at the forefront of anticancer immune responses | Q41819433 | ||
| Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies | Q42745781 | ||
| Henry S. Kaplan Distinguished Scientist Award Lecture 2007. The remarkable yin and yang of tumour hypoxia | Q43009524 | ||
| New antimetastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2-nitroimidazole-acetamide, TX-1877, and its analogues | Q43542768 | ||
| P433 | issue | 10 | |
| P921 | main subject | hypoxia | Q105688 |
| P304 | page(s) | 536-545 | |
| P577 | publication date | 2016-11-08 | |
| P1433 | published in | Cancer Investigation | Q325953 |
| P1476 | title | Hypoxia: A Double-Edged Sword in Cancer Therapy | |
| P478 | volume | 34 |
| Q91830459 | B7-H3 Induces Ovarian Cancer Drugs Resistance Through An PI3K/AKT/BCL-2 Signaling Pathway |
| Q50025483 | Baicalin induces cellular senescence in human colon cancer cells via upregulation of DEPP and the activation of Ras/Raf/MEK/ERK signaling |
| Q90195204 | Cellular Stress Responses in Radiotherapy |
| Q92557315 | Colon cancer cells secrete exosomes to promote self-proliferation by shortening mitosis duration and activation of STAT3 in a hypoxic environment |
| Q92703023 | Energy Metabolism in Cancer: The Roles of STAT3 and STAT5 in the Regulation of Metabolism-Related Genes |
| Q90678032 | Exercise as Adjunct Therapy in Cancer |
| Q98463685 | Flavagline synthetic derivative induces senescence in glioblastoma cancer cells without being toxic to healthy astrocytes |
| Q112284336 | Network Pharmacology-Based Study on the Active Component and Mechanism of the Anti-Non-Invasive and Invasive Bladder Urothelial Carcinoma Effects of Zhuling Jisheng Decoction |
| Q90221767 | PO2-based biodosimetry evaluation using an EPR technique acts as a sensitive index for chemotherapy |
| Q64071649 | Prognostic role of diffusion weighted and dynamic contrast-enhanced MRI in loco-regionally advanced head and neck cancer treated with concomitant chemoradiotherapy |
| Q90341495 | Roles of Ceramides and Other Sphingolipids in Immune Cell Function and Inflammation |
| Q90732409 | Saikosaponin-d Inhibits the Hepatoma Cells and Enhances Chemosensitivity Through SENP5-Dependent Inhibition of Gli1 SUMOylation Under Hypoxia |
| Q38644800 | The Many Faces of Long Noncoding RNAs in Cancer |
| Q94552664 | Upregulation of lncRNA AGAP2-AS1 is an independent predictor of poor survival in patients with clear cell renal carcinoma |
Search more.